Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||23814 + Tivozanib|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|23814||NOTCH1 Antibody 2||23814 is a monoclonal antibody that binds to the Notch1 ligand-binding domain and inhibits ligand-mediated signaling, potentially resulting in decreased tumor growth (PMID: 25995436).|
|Tivozanib||Fotivda||AV-951|AV951|KIL-8951|KRN 951|KRN-951||VEGFR Inhibitor (Pan) 33||Fotivda (tivozanib) inhibits VEGFR1-3, which may result in decreased tumor angiogenesis and proliferation and increased cell death (PMID: 23788831, PMID: 31810797, PMID: 32547647). Fotivda(tivozanib) is FDA approved for use in adult patients with relapsed or refractory advanced renal cell carcinoma who have received two or more prior systemic therapies (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|